Circle November 11 on your calendar

Monday delivered the clearest possible demonstration of what a drug binary event can do. ACADIA Pharmaceuticals fell about 22% after disclosing that remlifanserin narrowly missed the primary endpoint of the Phase 2 RADIANT study in Alzheimer’s disease psychosis. The p-value on the primary measure landed at 0.0603, just shy of statistical significance. ACADIA has said it still views the dataset as Phase 3 enabling and plans to present detailed safety and efficacy results at CTAD in Boston, November 16–19, 2026. Close enough to continue into Phase 3. Not close enough to prevent roughly a quarter of the company’s market value from vanishing by the close.

It was another reminder of how unforgiving the calendar can be. Novartis’s pelacarsen, which reduced Lp(a) by about 78%, produced no reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON trial, with results presented at the American Heart Association Scientific Sessions in Chicago on November 7, 2026. Novo Nordisk’s ziltivekimab showed expected target engagement in the ZEUS outcomes trial and also failed to reduce major adverse cardiovascular events. Steven Nissen, who led Lp(a)HORIZON, said the neutral finding was unexpected and surprising. The biotech calendar does not space these moments out neatly.

ACAD’s commercial business is not the problem. Q3 revenues reached $342 million, up 22% year-over-year, with Nuplazid generating $202 million and Daybue a record $140 million, up 39%. The company ended the quarter with $976 million in cash and guided full-year revenue to $1.265–$1.295 billion. Canaccord raised its price target to $38. That gap captures the entire debate: does the remlifanserin Phase 3 path carry meaningful value, or do Nuplazid and Daybue carry the whole load?

Where the Options Opportunity Lives

The ACAD move is now priced. The forward question is which event triggers the next comparable swing. ACADIA will present full RADIANT Phase 2 data at the CTAD conference in Boston, November 16–19, 2026. Full-data presentations after a topline miss can either deepen a selloff or stabilize it, depending on what subgroup trends reveal.

Elsewhere on the calendar, Summit Therapeutics has a PDUFA goal date of November 14, 2026 for its BLA for ivonescimab in combination with chemotherapy in EGFR-mutated non-small cell lung cancer after tyrosine kinase inhibitor therapy, and Capricor’s Deramiocel BLA has a PDUFA target action date of November 22, 2026. These are defined dates with binary outcomes, exactly the structure where debit spreads tend to offer the clearest asymmetry relative to premium paid.

The Beast Verdict

ACAD’s one-day collapse is not a trade to chase. It is a lesson in how quickly a binary catalyst resolves and how violently price moves when it does. The actionable point: with implied volatility elevated across CNS and cardiometabolic names after a string of high-profile neutral outcomes, defined-risk structures around upcoming readouts deserve serious attention. The November calendar is crowded. Pick the catalyst with the clearest edge, size positions at a level where a total loss on premium is acceptable, and let the event do the work.